{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:04:34Z","timestamp":1768435474648,"version":"3.49.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.det.2018.02.016","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T02:47:56Z","timestamp":1524710876000},"page":"335-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Drugs on the Horizon for Chronic Pruritus"],"prefix":"10.1016","volume":"36","author":[{"given":"Matthew W.","family":"McEwen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Fite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the International Forum for the Study of Itch","volume":"87","author":"Stander","year":"2007","journal-title":"Acta Derm Venereol"},{"issue":"2 Pt 1","key":"10.1016\/j.det.2018.02.016_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0190-9622(98)70087-8","article-title":"How should we define itching?","volume":"39","author":"Savin","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2133.2004.06058.x","article-title":"Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study","volume":"151","author":"Dalgard","year":"2004","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"17","key":"10.1016\/j.det.2018.02.016_bib5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMcp1208814","article-title":"Clinical practice. Chronic pruritus","volume":"368","author":"Yosipovitch","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2340\/00015555-0371","article-title":"Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.det.2018.02.016_bib7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","article-title":"The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis","volume":"143","author":"Yosipovitch","year":"2000","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2133.1990.tb04195.x","article-title":"Anxiety and depression in patients with chronic urticaria and generalized pruritus","volume":"123","author":"Sheehan-Dare","year":"1990","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dth.12025","article-title":"Understanding the pathophysiology of itch","volume":"26","author":"Garibyan","year":"2013","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib10","first-page":"456","article-title":"Pathogenesis of pruritus","volume":"9","author":"Stander","year":"2011","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"issue":"3","key":"10.1016\/j.det.2018.02.016_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2340\/00015555-1829","article-title":"A\u00a0Th2 cytokine interleukin-31 signature in a case of sporadic lichen amyloidosis","volume":"95","author":"Dousset","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.det.2018.02.016_bib14","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7","key":"10.1016\/j.det.2018.02.016_bib15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin","volume":"96","author":"Nattkemper","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.det.2018.02.016_bib16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2340\/00015555-2047","article-title":"Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis","volume":"95","author":"Roblin","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","article-title":"Antipruritic treatment with systemic mu-opioid receptor antagonists: a review","volume":"63","author":"Phan","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2018.02.016_bib18","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.jid.5700942","article-title":"Possible roles of epidermal opioid systems in pruritus of atopic dermatitis","volume":"127","author":"Tominaga","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2133.2011.10347.x","article-title":"Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch","volume":"165","author":"Taneda","year":"2011","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2018.02.016_bib20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40265-017-0746-9","article-title":"Chronic pruritus: current and emerging treatment options","volume":"77","author":"Pereira","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.det.2018.02.016_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-3-662-44605-8_14","article-title":"NK-1 antagonists and itch","volume":"226","author":"Stander","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12885-017-3194-8","article-title":"Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature","volume":"17","author":"Song","year":"2017","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.det.2018.02.016_bib23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","article-title":"Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study","volume":"13","author":"Santini","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib24","doi-asserted-by":"crossref","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"Stander","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5021\/ad.2016.28.1.124","article-title":"Treatment for refractory pruritus using oral aprepitant","volume":"28","author":"Huh","year":"2016","journal-title":"Ann Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.016_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1517\/14656566.2016.1127355","article-title":"Advances in therapeutic strategies for the treatment of pruritus","volume":"17","author":"Stull","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.det.2018.02.016_bib27","unstructured":"Menlo therapeutics announces successful pruritus reduction results from phase 2 serlopitant trial (TCP-102) in 127 subjects with prurigo nodularis [press release]. 2017. Results presented at the 2017 American Academy of Dermatology (AAD) meeting. Orlando, March 3-7, 2017."},{"issue":"8","key":"10.1016\/j.det.2018.02.016_bib28","first-page":"1014","article-title":"Randomized, double-blind, placebo-controlled phase 2 clinical trial of serlopitant effects on multiple measures of pruritus in patients with prurigo nodularis","volume":"97","author":"Stander","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.det.2018.02.016_bib29","first-page":"1015","article-title":"Serlopitant for treatment of chronic pruritus: results of a randomized, multicenter, double-blind, placebo-controlled phase 2 clinical trial","volume":"97","author":"Yosipovitch","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.det.2018.02.016_bib30","first-page":"875","article-title":"An investigational study of tradipitant for the treatment of chronic pruritus in patients with atopic dermatitis","volume":"95","author":"St\u00e4nder","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2018.02.016_bib31","unstructured":"Vanda's tradipitant improves itch and disease severity in patients with atopic dermatitis [press release]. 2017. Available at: http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=2300433. Accessed September 21, 2017."},{"key":"10.1016\/j.det.2018.02.016_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","article-title":"Targeting itch with ligands selective for kappa opioid receptors","volume":"226","author":"Cowan","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib33","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib34","doi-asserted-by":"crossref","first-page":"e0178991","DOI":"10.1371\/journal.pone.0178991","article-title":"Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses","volume":"12","author":"Kamimura","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.det.2018.02.016_bib35","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","article-title":"Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial","volume":"47","author":"Kumada","year":"2017","journal-title":"Hepatol Res"},{"issue":"3","key":"10.1016\/j.det.2018.02.016_bib36","first-page":"1","article-title":"CR845 (Difelikefalin), a kappa receptors agonist in phase III by CARA therapeutics: a case of 'spin' in scientific writing?","volume":"2","author":"Keppel Hesselink","year":"2017","journal-title":"Journal of Pharmacology & Clinical Research"},{"key":"10.1016\/j.det.2018.02.016_bib37","unstructured":"Cara therapeutics announces positive top-line data from part A of a phase 2\/3 trial of I.V. CR845 in chronic kidney disease-associated pruritus [press release]. 2017."},{"issue":"3","key":"10.1016\/j.det.2018.02.016_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/1756283X16633050","article-title":"New and emerging therapies for\u00a0the treatment of irritable bowel syndrome: an update for gastroenterologists","volume":"9","author":"Foxx-Orenstein","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.det.2018.02.016_bib39","unstructured":"McGuire D. Safety, pharmacokinetics and preliminary efficacy of asimadoline in pruritus associated with atopic dermatitis. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02475447."},{"key":"10.1016\/j.det.2018.02.016_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12882-015-0043-3","article-title":"Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus","volume":"16","author":"Hawi","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.det.2018.02.016_bib41","unstructured":"Sciascia T. Study of nalbuphine HCl ER tablets in patients with prurigo nodularis. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02174419."},{"key":"10.1016\/j.det.2018.02.016_bib42","unstructured":"Sciascia T. Open label extension study of nalbuphine HCl ER in patients with prurigo nodularis. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02174432."},{"key":"10.1016\/j.det.2018.02.016_bib43","unstructured":"Sciascia T. Study of nalbuphine HCl ER tablets in hemodialysis patients with uremic pruritus. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02143648."},{"key":"10.1016\/j.det.2018.02.016_bib44","unstructured":"Sciascia T. Open label extension study of nalbuphine HCl ER in hemodialysis patients with uremic pruritus. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02143973."},{"issue":"9","key":"10.1016\/j.det.2018.02.016_bib45","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor a antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2018.02.016_bib46","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: first global approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.det.2018.02.016_bib47","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/ijd.13236","article-title":"Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials","volume":"55","author":"Strober","year":"2016","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib49","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2016.07.034","article-title":"Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials","volume":"75","author":"Kimball","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2018.02.016_bib50","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/jdv.14211","article-title":"Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3","volume":"31","author":"Leonardi","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib51","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A\u00a0prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, Phase 3 NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.02.016_bib53","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.02.016_bib54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10093","key":"10.1016\/j.det.2018.02.016_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.det.2018.02.016_bib56","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib57","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.det.2018.02.016_bib58","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/1346-8138.13956","article-title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial","volume":"44","author":"Abe","year":"2017","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of alopecia areata with tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/09546634.2014.906033","article-title":"Application of the itch severity score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses","volume":"26","author":"Mamolo","year":"2015","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.det.2018.02.016_bib61","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","article-title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","volume":"75","author":"Feldman","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.016_bib62","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.02.016_bib63","unstructured":"AbbVie's upadacitinib (ABT-494) meets primary endpoint in phase 2b study in atopic dermatitis [press release]. 2017. Available at: https:\/\/news.abbvie.com\/news\/abbvies-upadacitinib-abt-494-meets-primary-endpoint-in-phase-2b-study-in-atopic-dermatitis.htm. Accessed September 23, 2017."},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2011.10217.x","article-title":"Targeted treatment of pruritus: a look into the future","volume":"165","author":"Tey","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib65","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/1346-8138.13644","article-title":"One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases","volume":"44","author":"Yagami","year":"2017","journal-title":"J\u00a0Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J\u00a0Dermatol"},{"issue":"S102","key":"10.1016\/j.det.2018.02.016_bib67","first-page":"95","article-title":"A\u00a0phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389), a potent, oral histamine H4 receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults","volume":"71","author":"Werfel","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.det.2018.02.016_bib68","unstructured":"Ziarco reports positive phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients [press release]. 2016. Available at: https:\/\/globenewswire.com\/news-release\/2016\/06\/13\/847881\/10163430\/en\/Ziarco-Pharma-Ltd-Ziarco-reports-positive-Phase-2a-study-results-with-ZPL-389-in-moderate-to-severe-atopic-dermatitis-patients.html. Accessed October 1, 2017."},{"issue":"10","key":"10.1016\/j.det.2018.02.016_bib69","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1365-2222.2007.02811.x","article-title":"A\u00a0double-blind, placebo-controlled trial of montelukast in adult atopic eczema","volume":"37","author":"Friedmann","year":"2007","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib70","first-page":"50","article-title":"Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients","volume":"11","author":"Mahmudpour","year":"2017","journal-title":"Iran J Kidney Dis"},{"issue":"10074","key":"10.1016\/j.det.2018.02.016_bib71","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.det.2018.02.016_bib72","unstructured":"Marschall HU. IBAT inhibitor A4250 for cholestatic pruritus. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02360852."},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib73","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S0168-8278(17)30445-2","article-title":"The Ileal Bile Acid Transport inhibitor A4250 decreases pruritus and serum bile acids in cholestatic liver diseases - an ongoing multiple dose, open-label, multicentre study","volume":"66","author":"Baumann","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib74","first-page":"8","article-title":"TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery","volume":"62","author":"Yun","year":"2011","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.det.2018.02.016_bib75","unstructured":"Kim B. A study to evaluate the safety and efficacy of PAC-14028 cream in adults with atopic dermatitis. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02757729."},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib76","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/pr.112.006163","article-title":"Unravelling the mystery of capsaicin: a tool to understand and treat pain","volume":"64","author":"O'Neill","year":"2012","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib77","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5021\/ad.2016.28.1.86","article-title":"Considerable variability in the efficacy of 8% capsaicin topical patches in the treatment of chronic pruritus in 3 patients with notalgia paresthetica","volume":"28","author":"Andersen","year":"2016","journal-title":"Ann Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2340\/00015555-2472","article-title":"Cost-effectiveness of an 8% capsaicin patch in the treatment of brachioradial pruritus and notalgia paraesthetica, two forms of neuropathic pruritus","volume":"97","author":"Steinke","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.det.2018.02.016_bib79","first-page":"864","article-title":"Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up","volume":"95","author":"Misery","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.det.2018.02.016_bib80","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","article-title":"NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study","volume":"7","author":"Backonja","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.det.2018.02.016_bib81","unstructured":"FDA approves eucrisa for eczema [press release]. 2016. Available at: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm533371.htm. Accessed September 11, 2017."},{"issue":"3","key":"10.1016\/j.det.2018.02.016_bib82","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib83","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","article-title":"Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis","volume":"77","author":"Eichenfield","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib84","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaad.2016.04.001","article-title":"OPA-15406, a\u00a0novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study","volume":"75","author":"Hanifin","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2018.02.016_bib85","unstructured":"AD breakthrough? Medimetriks' MM36 achieves rapid itch relief, safety in phase 2 study [press release]. 2017. Available at: http:\/\/practicaldermatology.com\/dermwire\/2017\/09\/06\/ad-breakthrough-medimetriks-mm36-achieves-rapid-itch-relief-safety-in-phase-2-study. Accessed September 11, 2017."},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib86","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0022-3565(24)37206-4","article-title":"Inhibition of neuronal Na+ channels by antidepressant drugs","volume":"284","author":"Pancrazio","year":"1998","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.55.1.1","article-title":"Topical and peripherally acting analgesics","volume":"55","author":"Sawynok","year":"2003","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.det.2018.02.016_bib88","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.10.030","article-title":"Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability","volume":"76","author":"Lee","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib89","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jaad.2017.02.056","article-title":"The role of cannabinoids in dermatology","volume":"77","author":"Mounessa","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.02.016_bib90","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.jaad.2017.05.023","article-title":"Response to: \"the role of cannabinoids in dermatology\"","volume":"77","author":"Liszewski","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.016_bib91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1468-3083.2007.02351.x","article-title":"Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)","volume":"22","author":"Eberlein","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2018.02.016_bib92","first-page":"97","article-title":"Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study","volume":"13","author":"Szepietowski","year":"2005","journal-title":"Acta Dermatovenerol Croat"},{"issue":"9","key":"10.1016\/j.det.2018.02.016_bib93","first-page":"801","article-title":"Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus","volume":"57","author":"Stander","year":"2006","journal-title":"Hautarzt"},{"issue":"8","key":"10.1016\/j.det.2018.02.016_bib94","first-page":"1021","article-title":"Prolonged antipruritic effect of botulinum toxin type A on cowhage-induced itch","volume":"97","author":"Nattkemper","year":"2017","journal-title":"Acta Derm Venereol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518300275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518300275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T23:10:13Z","timestamp":1751584213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518300275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0733863518300275"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.02.016","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs on the Horizon for Chronic Pruritus","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}